聚焦艾昆纬-IQVIA医疗技术数据为2型糖尿病治疗提供信息(英)-2026。The early benefit was especially clear among patients who initiated CGM within three months of starting GLP-1 therapy: at the 3-month follow-up, 61% of GLP-1 +CGM patients had a reduction in HbA1c status compared with 28% of GLP-1-only patients (Figure 4).
聚焦艾昆纬-IQVIA医疗技术数据为2型糖尿病治疗提供信息(英)-2026。The early benefit was especially clear among patients who initiated CGM within three months of starting GLP-1 therapy: at the 3-month follow-up, 61% of GLP-1 +CGM patients had a reduction in HbA1c status compared with 28% of GLP-1-only patients (Figure 4).
聚焦艾昆纬-IQVIA医疗技术数据为2型糖尿病治疗提供信息(英)-2026。The early benefit was especially clear among patients who initiated CGM within three months of starting GLP-1 therapy: at the 3-month follow-up, 61% of GLP-1 +CGM patients had a reduction in HbA1c status compared with 28% of GLP-1-only patients (Figure 4).
覆盖 2026 年,全文共 13 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了医疗、艾昆纬等议题。